Updates are available Correction dated 2023-07-26
Click to view Correction: https://doi.org/10.1038/s41586-023-06445-2
-
Authors
Emont, Margo P. https://orcid.org/0000-0001-9873-2784
Jacobs, Christopher https://orcid.org/0000-0002-6034-1873
Essene, Adam L.
Pant, Deepti
Tenen, Danielle
Colleluori, Georgia https://orcid.org/0000-0002-4908-9873
Di Vincenzo, Angelica
Jørgensen, Anja M.
Dashti, Hesam
Stefek, Adam
McGonagle, Elizabeth https://orcid.org/0000-0001-9708-9272
Strobel, Sophie
Laber, Samantha
Agrawal, Saaket
Westcott, Gregory P. https://orcid.org/0000-0002-4321-3992
Kar, Amrita
Veregge, Molly L.
Gulko, Anton
Srinivasan, Harini
Kramer, Zachary
De Filippis, Eleanna https://orcid.org/0000-0002-5622-6709
Merkel, Erin
Ducie, Jennifer
Boyd, Christopher G.
Gourash, William
Courcoulas, Anita
Lin, Samuel J.
Lee, Bernard T.
Morris, Donald
Tobias, Adam
Khera, Amit V.
Claussnitzer, Melina
Pers, Tune H. https://orcid.org/0000-0003-0207-4831
Giordano, Antonio
Ashenberg, Orr
Regev, Aviv
Tsai, Linus T. https://orcid.org/0000-0002-0134-6949
Rosen, Evan D. https://orcid.org/0000-0003-4603-708X
- License Information
-
More Information
Article History
Received: 15 May 2021
Accepted: 4 February 2022
First Online: 16 March 2022
Change Date: 26 July 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-023-06445-2
Competing interests
: S.A. has served as a scientific consultant to Third Rock Ventures. A.V.K. has served as a scientific advisor to Sanofi, Amgen, Maze Therapeutics, Navitor Pharmaceuticals, Sarepta Therapeutics, Novartis, Verve Therapeutics, Silence Therapeutics, Veritas International, Color Health, Third Rock Ventures and Columbia University (NIH); received speaking fees from Illumina, MedGenome, Amgen, and the Novartis Institute for Biomedical Research; and received a sponsored research agreement from the Novartis Institute for Biomedical Research. M.C. holds equity in Waypoint Bio and is a member of the Nestle Scientific Advisory Board. A.R. is a co-founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas Therapeutics and a scientific advisory board member of Thermo Fisher Scientific, Syros Pharmaceuticals, Asimov and Neogene Therapeutics. A.R. is also an employee of Genentech. All other authors declare no competing interests.
